EAU 2017: Familial and genetic factors: New SNPs and panels

London, England (UroToday.com) Prostate cancer has normal distribution in the population. The challenge is to find and treat the more aggressive disease and hopefully not treat the low risk disease. In this presentation Professor Eeles described the new OncoArray chip, identifying 65 small nucleotide polymorphisms (SNPs) correlated with prostate cancer.

The prostate cancer component of this chip is part of a much larger study examining additional cancers such as breast, lung, colorectal and ovarian. A total of 67 groups around the world provided over 100,000 samples of prostate cancer patients. Only 20% of the samples were of aggressive cases.

The SNP profile of the OncoArray chip enable us to receive a polygenic risk score. It was demonstrated that the highest 1% risk category had a 5.72 (95% CI 5.04-6.49) relative risk of having prostate cancer in an individual’s life time compared to the 25-75% risk category. The top 10% risk category had a 2.7 relative risk, while the lowest 1% risk category had a relative risk of 0.17 (95% CI 0.13-0.23). These significant and exciting data are currently being incorporated into patient counseling in the UK, especially in those patients with a significant family history of prostate cancer.

Speaker(s): Professor Rosalind Eeles, London (GB)

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto
Twitter: @GoldbergHanan

at the #EAU17 - March 24-28, 2017- London, England

Login